Diphenhydramine, a sedative histamine H 1 -receptor (H 1 R) antagonist, was evaluated as a probe to measure drug/H þantiporter function at the blood-brain barrier. In situ brain perfusion experiments in mice and rats showed that diphenhydramine transport at the blood-brain barrier was saturable, following Michaelis-Menten kinetics with a K m ¼ 2.99 mM and V max ¼ 179.5 nmol s À1 g À1 . In the pharmacological plasma concentration range the carrier-mediated component accounted for 77% of diphenhydramine influx while passive diffusion accounted for only 23%. [ 14 C]Diphenhydramine blood-brain barrier transport was proton and clonidine sensitive but was influenced by neither tetraethylammonium, a MATE1 (SLC47A1), and OCT/OCTN (SLC22A1-5) modulator, nor P-gp/Bcrp (ABCB 1a/1b /ABCG2) deficiency. Brain and plasma kinetics of [ 11 C]diphenhydramine were measured by positron emission tomography imaging in rats.
Introduction
For many years, passive diffusion was thought to be the sole mechanism controlling drug permeation through the blood-brain barrier (BBB) and the subsequent exposure of the central nervous system (CNS) to the drug. In the 1990s, the discovery of unidirectional membrane transporters from the ATP-binding cassette (ABC) family at the BBB challenged this assumption. 1 P-glycoprotein (P-gp/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) are the main ABC transporters at the BBB. 2, 3 They mediate the exit of substrates across the luminal BBB membrane back to the blood compartment, with a substantial impact on their CNS distribution and effects. 2 Considerable efforts are being made to assess the functional properties of transporters expressed at the BBB and predict their implications for CNS pharmacokinetics and pharmacodynamics. 2 Positron emission tomography (PET) imaging using radiolabeled transporter substrates is an appealing approach for the noninvasive study of transporter function at the BBB in animals and humans, in health and disease. 4 It provides a unique tool to evaluate the risk of drug-drug interactions (DDI) involving transporter substrates and inhibitors and their impact on brain exposure to the drug in vivo, 5 in particular the impact of ABC-transporter function at the BBB. 6, 7 Several studies have revealed that the brain uptake of many psychoactive drugs is saturable, further challenging the picture of passive diffusion as the exclusive regulator of adequate brain exposure. Diphenhydramine (2-(diphenylmethoxy)-N,N-dimethylethanamine) is a clinically approved histamine H 1 -receptor (H 1 R) antagonist with known sedative effects. 8 In situ brain perfusion experiments have shown a saturable uptake transport mechanism for diphenhydramine at the rat BBB. 9 Recent brain microdialysis experiments have also suggested the importance of diphenhydramineinflux transport at the BBB in different species including rats, dogs, and nonhuman primates. 10 The functional characterization of this transport remains to be established in vivo.
Several in vivo/in situ studies have provided evidence of a novel and molecularly unknown drug transporter that controls the permeation of many CNS compounds across the mouse BBB. [11] [12] [13] This specific transport has also been observed in vitro using rodent and human immortalized brain endothelium or intestinal cell lines. [14] [15] [16] [17] Notably, these studies have elucidated the functional properties of the transporter involved, characterizing it as a cationic drug/proton (H þ )-antiporter. This so-called drug/H þ -antiporter function does not correspond to any of the other solute carrier (SLC) drug transporters identified at the molecular level: OCT1-3 (SLC22A1-3), OCTN (SLC22A4-5), or MATE1 (SLC47A1). [14] [15] [16] [17] So far, identified H þ -antiporter substrates mainly include cationic tertiary/secondary amines with CNS activity, such as cocaine, 12 clonidine, 11 nicotine, 13 oxycodone, 17 and ecstasy. 16 Some H þ -antiporter function inhibitor drugs have been screened and identified using in vitro BBB models 14 or in situ brain perfusion 11 ; saturation or inhibition of H þ -antiporter function using known inhibitors occurs at blood concentrations too toxic or unreachable for in vivo studies. 14 The identification of this H þ -antiporter function at the BBB raises questions as to its impact on the variability of the response to CNS substrate drugs, which remains a major issue in neuropharmacology. Thus, probes are needed to selectively investigate the pathophysiological parameters that modulate H þ -antiporter function at the BBB. In the present study, we used in situ brain perfusion in rats to investigate the qualitative and quantitative contributions of passive diffusion and the H þ -antiporter function to diphenhydramine transport at the BBB, and thus consider diphenhydramine as a specific and selective probe to study H þ -antiporter function at the BBB. The pharmacokinetic properties of carbon-11 radiolabeled diphenhydramine were evaluated to validate its use as a PET probe for the noninvasive study of drug/H þ -antiporter function in vivo.
Materials and methods Animals
Experiments were performed with male Sprague Dawley rats (285 AE 40 g; 7-9 weeks; Janvier, Genest, France). The 90 rats were housed in a controlled environment (22 AE 3 C; 55 AE 10% relative humidity) and a 12 h dark/light cycle, with access to food and tap water ad libitum. All studies involving animals are reported in accordance with ARRIVE guidelines for reporting experiments and complied with the ethical rules of the European directive (210/63/EU) for experimentation with laboratory animals; they were approved by the ethics review committee of Paris Descartes University (approvals no. 12-183/12-186/2012).
Chemicals and radiochemicals
Diphenhydramine hydrochloride and tetraethylammonium hydrochloride (TEA) were purchased from Inresa (Strasbourg, France) and Sigma (St Quentin Fallavier, France), respectively. All other chemicals were purchased from Sigma. [ 14 C]Diphenhydramine (26 Â 10 10 Bq mmol À1 ) and 3 H-inulin (48 Â 10 10 Bq mmol À1 ) was purchased from Moravek (La Brea, CA, US) and Perkin Elmer Life Sciences (Courtaboeuf, France), respectively. Ready to inject [ 11 C]-diphenhydramine was synthesized from the corresponding desmethyl precursor (N-desmethyl-diphenhydramine; 1 mg) using [ 11 C]methyl-triflate in a TRACERlab TM FX CPro module. Radiomethylation was carried out in acetone (400 ml) in the presence of 3 M sodium hydroxide (7 ml) at 120 C for 2 min. Semi-preparative HPLC purification (Agilent Zorbax Õ C18, 250 Â 9.4 mm, 5 mm; CH 3 CN/H 2 O/TFA 30/70/0.1 v/v/v) followed by formulation afforded radiochemically pure [ 11 C]diphenhydramine (1.5-3 GBq) within 45 min in 15% decay corrected yield (n ¼ 11).
BBB transport kinetics using in situ brain perfusion Experimental procedure. The qualitative and quantitative transport properties of [ 14 C]diphenhydramine were assessed in vivo at the BBB using the in situ brain perfusion method in rats. 18 The in situ carotid method replaces blood by an artificial perfusate fluid so that [ 14 C]diphenhydramine did not undergo peripheral metabolism. In this condition, the radiochemical purity of [ 14 C]diphenhydramine in the perfused brain was previously assessed. 9 The composition of the perfusate can be set up to study the effect of inhibitors, substrate concentrations, or specific electrolytic conditions that cannot be reached physiologically in vivo. Therefore, the transport properties and functional/ biochemical features of the diffusion processes through the living BBB can be characterized regardless of the peripheral kinetics or toxicity of tested conditions.
Once anesthetized with a mixture of xylazine and ketamine at 4-80 mg kg À1 , briefly the right carotid arteries were exposed and a catheter was inserted into the right common carotid artery after ligation of the appropriate vessels. 19 The catheter was connected to a syringe containing the perfusion fluid. The thorax was then opened, the heart was cut and perfusion started immediately at a flow rate of 10 ml min À1 in rats. 18 At this time, the perfusion fluid replaces all the blood in the right brain vasculature. After 60 s perfusion, animals were decapitated and the brain removed from the skull and dissected on ice. Carbon-14 and tritium radioactivity were counted in the whole or selected regions of the right brain hemisphere, and perfusate aliquots using a Tri-Carb 2810TR counter (Perkin Elmer).
Each animal was perfused with protein-free Krebs carbonate buffer physiological saline containing (mM): 128 NaCl, 24 NaHCO 3 , 4.2 KCl, 2.4 NaH 2 PO 4 , 1.5 CaCl 2 , 0.9 MgSO 4 , and 9 D-glucose. The perfusion fluid pH (pH e ) was adjusted and checked with a digital pH meter (AE 0.05 pH units) immediately before perfusion. The proton dependency of diphenhydramine transport was assessed under conditions of nonphysiological vascular or intracellular pH modifications. Hydrochloric acid was added to the gassed perfusion fluid to bring the pH of the perfusion fluid to 6.40. In some experiments, NH 4 Cl (30 mM) was added in the perfusion fluid (final pH of 7.40) to modify intracellular pH (pH i ). The perfusion fluid was gassed with 95% O 2 /5% CO 2 for pH control (7.40), unless otherwise specified, and warmed to 37 C. [ 14 C]Diphenhydramine (4 Â 10 3 Bq ml À1 ; $1.4 mmol l À1 ) and [ 3 H]inulin (11 Â 10 3 Bq ml À1 ), a vascular integrity marker, were finally added to the solution, immediately before the start of perfusion.
Cis-inhibition experiments were carried out to confirm the involvement of the drug H þ /antiporter function. The concentrations were selected to obtain a modulation rather than to reflect the relevance of in vivo DDI, as these unbound concentrations selected cannot be produced by systemic administration. TEA (20 mM) a known prototypical inhibitor of OCT, OCTN, and MATE was shown not to interact with H þ /antiporter function. 11, 12, 16, 17 Clonidine (10 mM) was used as a competitive inhibitor of H þ /antiporter function at the BBB. 11 Calculation of kinetic parameters. Calculations were done as previously described. 19 The brain vascular volume was estimated using the vascular marker
where X * (dpm g À1 ) is the tritium amount in the tissue sample and C perf * (dpm ml À1 ) its concentration in the perfusion fluid. The data for any animal whose V v was above the normal value 18 was excluded from the study.
The apparent tissue distribution volume (V brain , ml g À1 ) was calculated as
where X tissue (dpm g À1 ) is the calculated amount of [ 14 C]diphenhydramine from the right brain and C perf (dpm ml À1 ) its concentration in the perfusion fluid. This total activity was corrected for ''vascular'' contamination using the V v subtraction
where X tot (dpm g À1 ) is the total quantity of [ 14 C]diphenhydramine measured in the sample tissue. The initial transport expressed as a K in (ml s À1 g À1 ) was calculated from
where T is the perfusion time (60 s). The diphenhydramine BBB flux (J in ¼ K in xC tot ) is composed of both a saturable (Michaelis-Menten term) and passive (unsaturable) components
where C tot (mmol l À1 ) is the total (unbound) diphenhydramine concentration in the perfusate (ranging from 1.4 mM to 30 mM), V max (nmol s À1 g À1 ) is the maximal velocity of transport, K m (mM) represents the concentration at the half-maximal carrier velocity. K passive (ml s À1 g À1 ) is an unsaturable component, which represents the rate of transport by passive diffusion. The data were fitted using nonlinear regression analysis. A relative value for the permeability of a compound into the tissue was obtained from the extraction parameter (E, %), where F is the vascular fluid flow rate (42 ml s À1 g À1 ) of the whole right hemisphere measured using [ 3 H]diazepam, a free passively diffusible totally extracted compound in mice and rats, 18 calculated as
In situ brain perfusion in mice. Additional in situ brain perfusion experiments were performed in mice in order to compare diphenhydramine kinetic parameters between mice and rats and investigate the influence of P-gp and Bcrp function at the BBB on diphenhydramine flux through the BBB using P-gp/Bcrp (Abcb1a -/-, Abcb1b -/-, Abcg2 -/-) triple knock-out mice. Methods and results of mice experiments are described in a supplementary information (available on the JCBFM website; see supplementary information link at the top of the online article).
[ 11 C]Diphenhydramine PET imaging
MicroPET scans were performed using an Inveon Õ microPET system (Siemens, Germany) in rats. Anesthesia was induced and thereafter maintained using 3 and 1. Images were reconstructed with the FOREþ OSEM2D algorithm including normalization, attenuation, scatter, and random corrections. Image analysis and quantification of radioactivity uptake were performed using Pmod Õ software (version 3.7, Switzerland). The Schiffer rat brain atlas was used to delineate brain regions and generate the corresponding time-activity curves (TACs). Radioactivity was corrected for carbon-11 decay, injected dose and animal weight to express the measurements in standardized uptake values (SUV). T max was defined as the time at which the maximum of the TAC curve (SUV max ) occurred.
PET-based estimation of [ 11 C]diphenhydramine brain uptake clearance was performed using the integration plot analysis from 0 to 2 min 20 considering the mean metabolite-corrected arterial input function measured in three additional rats. To that end, a catheter was inserted in the femoral artery of anesthetized rats. After [ 11 C]diphenhydramine injection, arterial blood samples were withdrawn, centrifuged, and counted. Plasma samples withdrawn at 2, 5, 15, 30, and 60 min were used to estimate the fraction of parent [ 11 C]diphenhydramine in plasma using radio-HPLC analysis. Radio-HPLC system consisted of a quaternary gradient pump, an ASI100T autosampler, and a UVD170U UV-vis detector (Thermo Scientific, France) online with an LB-509 radioisotope detector (Berthold, France). [ 11 C]diphenhydramine and its radiometabolites were detected and separated using an Atlantis preparative T3 10 mm, 10 Â 250 mm at 25 C (Waters, France). The mobile phases consisted of 10 mM ammonium acetate in purified water (A) and acetonitrile (B). A linear gradient from 30 to 75% of B in 9 min was applied to the column at a flow rate of 5 ml min À1 . In these conditions, the retention time of diphenhydramine and N-desmethyldiphenhydramine was 8.5 and 7.5 min, respectively. Representative chromatograms are shown in a supplementary information (available on the JCBFM website; see supplementary information link at the top of the online article).
Additional rats were used to investigate the presence of radiometabolites in the brain. [ 11 C]Diphenhydramine (60.7 AE 7.6 MBq) was injected and rats were decapitated after either 15 or 60 min (n ¼ 3 in each condition). Brains were added 200 ml purified water before sonication at 4 C. Brain homogenates were mixed with 700 ml acetonitrile. The extracts (400 ml) were injected onto the radio-HPLC system described above.
Statistical analysis
In situ brain perfusion data are presented as means AE SD. One way ANOVA and post hoc test (Dunnett) or Student's two-tailed unpaired t-test were used to identify significant differences and statistical significance was set at p < 0.05. The transport parameters (K m , V max , K passive ) were estimated by plotting drug flux data against total concentration using equation (5) and nonlinear regression with WinNonlin Õ software. The errors associated with these parameters are asymptotic standard errors returned by the nonlinear regression routine.
Results

Characterization of diphenhydramine transport across the luminal BBB
Passive and carrier-mediated transport components. Figure 1 displays the concentration dependency of [ 14 C]diphenhydramine BBB flux (J in ) measured at pH e 7.40. Carrier-mediated flux was calculated by subtracting unsaturated diphenhydramine BBB flux from the total flux and was plotted against total diphenhydramine (unbound) vascular concentration. The regression analysis of the carrier-mediated flux was best fitted with a Hill coefficient of 1. The carrier-mediated flux model yielded an apparent K m of 2.98 AE 1.4 mM and a V max of 179.5 AE 44.5 nmol s À1 g À1 . The total BBB passive diffusion component at pH 7.40 yielded a K passive of 7.28 AE 1.58 ml s À1 g À1 for diphenhydramine, equivalent to a brain extraction E passive of 17.2%. A comparison of the in vivo passive ($7.3 ml s À1 g À1 ) and carriermediated ($24.5 ml s À1 g À1 ) transport rates suggests that the carrier-mediated influx of diphenhydramine through the BBB is $3.36 times greater than its passive diffusion when the concentration range is less than the apparent carrier-mediated K m . The global (passive and carrier-mediated) brain transport rate for diphenhydramine under unsaturated conditions was 31.8 ml s À1 g À1 , which corresponds to an extraction E total,brain of 75.2%.
The carrier-mediated flux was higher than the passive diffusion flux for diphenhydramine concentrations below 21.6 mM, the concentration at which the fluxes were equal (equation (5)), as also shown graphically by the curve intercept (Figure 1) .
The pH i or pH e was manipulated to obtain biochemical information for the characterization of the proton effect on [ 14 C]diphenhydramine transport across the BBB. The proportion of neutral and cationic species of diphenhydramine depends on the vascular pH e , which can be estimated using a basic pK a value of 8.98. Diphenhydramine is 0.26% neutral at pH e 6.40 and 2.6% neutral at pH e 7.40. Transport (K in ) of [ 14 C]diphenhydramine measured without adding unlabeled diphenhydramine increased significantly (274%) between pH e 6.40 and 7.40 (Figure 2(a) ). Adding unlabeled diphenhydramine (10 mM) significantly decreased the [ 14 C]diphenhydramine K in at pH 6.40 and 7.40 by 2.5 -and 2.3-fold, respectively, suggesting the involvement of a saturable carrier-mediated system (Figure 2) . To limit the confounding effect of the proportion of neutral [ 14 C]diphenhydramine in the perfusate and thus more clearly reveal the effect of protons on transporter activity, [ 14 C]diphenhydramine transport (pH e 7.40) was evaluated using a protocol that increased only the intracellular pH i . 11 [ 14 C ]Diphenhydramine was perfused with or without NH 4 Cl (30 mM) in the perfusate, adjusted to a pH e of 7.40. Modulation of the pH i induced a significant twofold reduction in the BBB transport of [ 14 C]diphenhydramine, suggesting a role for the H þ -antiporter function (Figure 2 ).
Cis-inhibition experiments. The sensitivity and selectivity of the transport were evaluated with TEA and clonidine, two known drugs that interact with different ranges of cationic transporters. TEA (20 mM) did not significantly affect [ 14 C]diphenhydramine transport (Figure 2(c) ), suggesting the lack of both the OCTN and MATE H þ -antiporters and OCT transporter functions. Clonidine (10 mM), a validated H þ -antiporter substrate and inhibitor, induced a significant 1.4-fold reduction (p < 0.001) in [ 14 C]diphenhydramine BBB transport (Figure 2 ). The effect of unlabeled diphenhydramine (10 mM) coperfusion on [ 14 C]diphenhydramine transport was measured in different brain regions. The decrease in [ 14 C]diphenhydramine transport ranged from 2.8 -to 4.0-fold and was significant in all brain regions (Figure 2 (c); P < 0.001).
[ 11 C]Diphenhydramine PET imaging Figure 3 shows the accumulation and distribution of radioactivity in the rat brain after [ 11 C]diphenhydramine. Radioactivity was homogeneously distributed within the brain parenchyma. Figure 4 displays the mean TACs obtained in the brain after [ 11 C]diphenhydramine injection. Radioactivity peaked Figure 2 . Modulation of [ 14 C]diphenhydramine transport across the rat luminal blood-brain barrier (BBB) measured by in situ rat brain perfusion. (a) Effect of cis-inhibition using clonidine 10 mM or tetraethylammonium (TEA) 20 mM as well as of the increase of the BBB pH i (NH 4 Cl; 30 mM) on [ 14 C]diphenhydramine transport (K in ; ml s À1 g À1 ; n ¼ 4-5). (b) Effect of Krebs carbonate perfusion buffer at a pH e of 6.40 or 7.40 on [ 14 C]diphenhydramine brain transport, with (black column; n ¼ 4) or without (white column; n ¼ 4) coperfusion with unlabeled diphenhydramine (DPH; 10 mM). (c) [ 14 C]Diphenhydramine brain transport in the whole right brain hemisphere (RH, n ¼ 6) and five right brain regions including the frontal cortex (FCx), parietal cortex (PCx), occipital cortex (OCx), hippocampus (Hp), and striatum (St), with (black column; n ¼ 4) or without (white column; n ¼ 4) coperfusion with unlabeled diphenhydramine (DPH; 10 mM), measured by in situ rat brain perfusion for 60 s. Data represent means AE SD. ***P < 0.001. rapidly (T max $ 2 min) followed by a fast washout. Regional analysis showed the absence of retention in specific brain regions, suggesting nonspecific binding to the brain (Figure 4 ). The nonspecific nature of the binding was confirmed by displacement experiments using 1 mg kg À1 unlabeled diphenhydramine. Displacement had no detectable impact on [ 11 C]diphenhydramine brain kinetics in any brain region (Figure 4) .
The study of the [ 11 C]diphenhydramine arterial input function showed that [ 11 C]diphenhydramine was metabolized, with unmetabolized [ 11 C]diphenhydramine accounting for 25 AE 3.4% of total radioactivity in the plasma at 60 min postinjection (Figures 4 and 5) . The resulting TACs of unmetabolized [ 11 C]diphenhydramine in the plasma are shown in Figure 4 .
[ 11 C]diphenhydramine brain uptake clearance (Cl uptake ), estimated from 0 to 2 min of acquisition, was 0.99 AE 0.18 ml min À1 cm À3 . No radiometabolites could be detected in the brain at 15 min, confirming the radiochemical purity of brain radioactivity in the distribution phase. Radiometabolite(s) accounted for only 25% of brain radioactivity at 60 min, suggesting poor BBB permeation of radiometabolite(s) compared to unmetabolized [ 11 C]diphenhydramine. Radio-HPLC analysis, based on the retention time of detected radiometabolite(s) (R t ¼ 2.3 min) indicated that these radiometabolite(s) did not correspond to N-desmethyldiphenhydramine (R t ¼ 7.5 min) ( Figure 5, Figure 3S ).
Discussion
In this study, we used in situ brain perfusion experiments to show that a pH-sensitive carrier-mediated flux, rather than passive diffusion, controls diphenhydramine transport across the BBB. This TEA-insensitive transport corresponds to known features of the H þ -antiporter function at the BBB, in accordance with previous in vivo studies in mice. 11, 12 These results validate diphenhydramine as a substrate probe for the study of H þ -antiporter function at the BBB. Diphenhydramine transport has an apparent BBB K m of 3.0 mM in rats and 4.4 mM in mice, which are similar to the properties of the H þ -antiporter-mediated transport of diphenhydramine (K m 4.1 mM) measured at the mouse blood-retina barrier. 21 These relatively high apparent K m values with regard to the blood concentrations suggest that diphenhydramine is transported by a ''low-affinity'' and high-capacity transporter. Therefore, the saturation of diphenhydramine transport is not likely to occur in vivo. The highest total (bound and unbound) pharmacological/ toxicological concentrations of diphenhydramine reported in the plasma in rodents and humans are lower than 40 mM. 22 These concentrations are several orders of magnitude lower than the K m and match the linear/proportional BBB kinetics (first-order kinetics) of transporter flux. Thus, toxicological concentrations are still in this proportional activity range of the transporter and far from the maximum velocity (zero-order kinetics reached above the K m ) of this transport system in vivo. Quantitative analysis of the passive and active transport components confirms that active influx controls 77% of total diphenhydramine uptake by the brain for concentrations lower than the K m , which include the usual micromolar pharmacological concentrations.
The diphenhydramine influx component reported here in rats has previously been demonstrated in sheep, 23 dogs, and nonhuman primates, 10 using the invasive brain microdialysis approach. These findings suggest the conservation of a carrier-mediated influx function at the BBB across animal species, possibly involving drug/H þ -antiporter function, as recently illustrated in the human hCMEC/D3 BBB cell line. 12, 14 So far, H þ -antiporter function at the BBB has been investigated using invasive and terminal animal experiments. However, PET imaging using radiolabeled H þ -antiporter substrates is an appealing approach for the noninvasive study of this specific transport system function at the BBB of animals and humans. 
